Swiss dental medtech vVARDIS has secured a strategic minority investment from Apollo-managed funds, in a deal that the company said makes it one of Europe’s few privately held healthcare unicorns. Financial terms were not disclosed.
The Zug-based company develops Curodont, a non-invasive treatment designed to address early-stage tooth decay without drilling. Apollo’s backing is set to support vVARDIS’ next phase of global growth and commercial expansion, including further rollout of its cavity treatment products across the US and Europe.
The investment highlights continued investor interest in healthcare companies developing less invasive treatment options, particularly in large and established care markets such as dentistry.
The Zug-based company develops Curodont, a non-invasive treatment designed to address early-stage tooth decay without drilling. Apollo’s backing is set to support vVARDIS’ next phase of global growth and commercial expansion, including further rollout of its cavity treatment products across the US and Europe.
The investment highlights continued investor interest in healthcare companies developing less invasive treatment options, particularly in large and established care markets such as dentistry.